The handbook of biological therapy : a guide to the use and safety of biological therapies in rheumatology, dermatology, and gastroenterology / Bruce Kirkham ... [and others].

Format:

Book

Contributor:

Kirkham, Bruce.

Language:

English

Subjects (All):

Biological products--Therapeutic use.

Biological products.

Tumor necrosis factor--Inhibitors.

Tumor necrosis factor.

Biological Products--therapeutic use.

Tumor Necrosis Factor Inhibitors.

Medical Subjects:

Biological Products--therapeutic use.

Tumor Necrosis Factor Inhibitors.

Physical Description:

xiv, 155 pages : illustrations ; 24 cm

Place of Publication:

Oxford ; New York : Oxford University Press, [2008]

Summary:

Drugs produced by molecular biological techniques, called the 'biologics', differ from the usual chemical medications. Their optimum use, and the detection and management of adverse events, pose a significant challenge to the clinician. Licences for new biologics continue to be granted, for the likes of rituximab, abatacept and certocizumals pegol. Intensive research is also defining new areas in which these drugs will be used in the future, increasing the number of practitioners using biologics. As the use of these drugs increases around the world, so the level of information needed by primary care practitioners and specialist prescribers needs to be expanded.

This book provides the practising clinician with a practical guide to the use of Tumour Necrosis Factor Blocking Therapy (TNF-blockers), an important new class of biologic therapy for rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis and psoriatic arthritis. It is a comprehensive distillation of the authors' clinical experience with these drugs, combined with data from diverse databases offering practical advice on their uses, specific indications, supporting clinical trial data and safety issues, with the aim of making the use of these drugs easier for the busy clinician.

All of the authors have been involved from the beginnings of the clinical trial programmes with these drugs and continue to use them in daily practice.

Contents:

TNF - tumour necrosis factor α xi

Mode of action of anti - TNF xii

TNF-blocking drugs in clinical use xiii

TNF-blocking drugs not in clinical use xiv

Section 1 TNF-blocker safety

Increased risk of infection 2

Tuberculosis 3

Opportunistic infections 7

Injection-site reactions 7

Allergic, hypersensitivity reactions, anaphylactic responses 7

Psoriasis 8

Infusion reactions (infliximab) 8

Malignancy and lymphoproliferative conditions 9

Drug-induced lupus-like reactions 12

Anti-drug antibodies (immunogenicity) 12

Congestive heart failure 13

Neurological 14

Hepatobiliary 15

Use in pregnancy 16

Lactation 17

Respiratory 17

Vaccinations 17

Use of TNF-blockers with other medications 18

Haematological 18

Postmarketing safety experience in Crohn's disease 18

Section 2 Rheumatology

Rheumatoid arthritis 27

Other rheumatological conditions 34

TNF-blocking therapy in ankylosing spondylitis and psoriatic arthritis 38

Ankylosing spondylitis 38

Psoriatic arthritis 44

Adalimumab (Humira) 48

Etanercept (Enbrel) 57

Infliximab (Remicade) 68

Certolizumab pegol (Cimzia) 79

Abatacept (Orencia) 81

Anakinra (Kineret) 89

B-cell depletion: Rituximab (Rituxan® [USA], Mab Thera® [Europe, Asia, South America]) 93

Section 3 Dermatology

Psoriasis 98

Approaches to management 99

Assessing disease severity 100

Important differences between psoriasis and rheumatoid arthritis 101

Biological therapy for psoriasis 101

Etanercept (Enbrel) 103

Infliximab (Remicade) 106

Adalimumab (Humira) 110

Efalizumab (Raptiva) 113

Alefacept (Amevive) 118

Section 4 Gastroenterology

Biological therapy in inflammatory bowel disease and Crohn's disease 122

Adalimumab (Humira) 131

Infliximab (Remicade) 135

Natalizumab (Tysabri) 143

Certolizumab pegol (Cimzia) 148.

Notes:

Includes bibliographical references and index.

ISBN:

9780199208166

0199208166

OCLC:

233545995